Abbott Launches World’s Smallest Rechargeable System with Remote Programming Capabilities to Treatment Movement Disorders

ABBOTT PARK, Ill., Jan. 25, 2024 /PRNewswire/ — Abbott (NYSE: ABT) announced today that it received approval from the U.S. Food and Drug Administration (FDA) to launch the Liberta RC™ DBS system, the world’s smallest rechargeable deep brain stimulation (DBS) device with remote programming, to treat people living with movement disorders.1+ The Liberta RC DBS system also requires the fewest recharges of any FDA-approved DBS system, needing only 10 recharge sessions a year for most people.2*